REGULATORY

Lixiana Now Set for Label Expansion; 11 Drugs to Get Orphan Tags

By Sakura Kono February 3, 2025

- Only subscribers can save articles.
  
  Sign In
  
  Subscribe

Japanese regulatory authorities are set to soon approve Daiichi Sankyo’s anticoagulant Lixiana (edoxaban) for a new indication of the prevention of thromboembolism in patients with chronic thromboembolic pulmonary hypertension. The Ministry of Health, Labor and Welfare (MHLW) on January 31…

To read the full story

Japan Approves CSL’s HAE Med Andembry, Tecentriq Sarcoma Use, and More
February 21, 2025

REGULATORY

MHLW Pharma Director Says Uniform Drug Price Hike “Not Realistic,” Targeted Support Preferred
January 9, 2026
MHLW Issues Guidance on Revised PMD Act Ahead of May Enforcement
January 6, 2026
MHLW Sets Up Drug Discovery Support Office Ahead of New Fund Launch
January 6, 2026
Ex-JPMA President Ueno Takes on New AMED Advisor Role
January 6, 2026
Cabinet OKs FY2026 Tax Reform Package, Creates Strategic Tech R&D Credit
January 5, 2026

Chuikyo Debate on FY2026 Drug Pricing Reform

Gist of FY2026 Drug Pricing Reform Outline

The Central Social Insurance Medical Council, a key Japanese reimbursement policy panel better known as Chuikyo, approved an outline of…

COMMENTARY

Wave of “World Firsts” Looms as 47 New Drug Candidates Line Up for 2026

By Shinya Sato

As many as 47 new drug candidates are expected to win approval or secure NHI price listing in Japan in…

COLUMN

AI: Your New HR BFF (Not Your Replacement!)

By Philip Carrigan

Let’s ditch the stuffy jargon and talk about AI in HR like real humans.One of the biggest myths floating around is that AI is coming to steal our jobs. Newsflash: that’s not happening. Sure, AI can handle the boring stuff…